Article Details
Retrieved on: 2024-06-14 13:07:54
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article explores the use of covalent Bruton's tyrosine kinase (BTK) inhibitors in treating Chronic Lymphocytic Leukemia (CLL), including specific drugs like ibrutinib and zanubrutinib. It connects to epidemiology by discussing treatment efficacy and patient demographics, and covers tags such as "Orphan drugs" and "Progression-free survival."
Article found on: www.pharmacytimes.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here